BIONi010-C with an APOE 2/2 genotype (with two functional alleles in contrast to BIONi010-C-6)

General

Cell Line

hPSCreg name BIONi010-C-52
Cite as:
BIONi010-C-52 (RRID:CVCL_C9MC)
Alternative name(s)
BIONi010-C with an APOE 2/2 genotype (with two functional alleles in contrast to BIONi010-C-6)
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
BIONi010-C
(BIONi010-C, K3P53)
BIONi010-C-13
(BIONi010-C + NGN2 #I7-26)
BIONi010-C-2
(BIONi010-C ApoE E3/E3 #H8 P32)
BIONi010-C-3
(BIONi010-C ApoE KO #KO30 P30)
BIONi010-C-15
(BIONi010-C +dox inducible NGN2-GFP)
BIONi010-C-25
(BIONi010-C heterozygous TREM2 KO)
BIONi010-C-6
(BIONi010-C ApoE E2/E2)
BIONi010-C-7
(BIONi010-C Trem2 R47H)
BIONi010-C-8
(BIONi010-C Trem2 T66M, #Y5-80)
BIONi010-C-9
(BIONi010-C CD33 KO)
BIONi010-C-17
(BIONi010-C TREM2 KO)
BIONi010-C-4
(BIONi010-C ApoE E4/E4 #B44 P27)
BIONi010-C-5
(BIONi010-C CD33 E2del #N14 P26)
BIONi010-C-70
(BIONi010-C with an APOE 2/2 genotype with an additional, homozygous christchurch mutation)
BIONi010-C-71
(BIONi010-C with an APOE 3/3 genotype with an additional, homozygous christchurch mutation)
BIONi010-C-51
(BIONi010-C TNNI3-mCherry reporter)
BIONi010-C-18
(BIONi010-C TBK1 KO)
BIONi010-C-19
(BIONi010-C IKBKE KO)
BIONi010-C-10
(HNF1AP291fsinsC +/- 54-5)
BIONi010-C-11
(HNF1AP291fsinsC -/- 66-1)
BIONi010-C-12
(HNF4ApR309C -/- 2-4)
BIONi010-C-53
(BIONi010-C with an APOE 3/3 genotype (with two functional alleles in contrast to BIONi010-C-2))
BIONi010-C-55
(BIONi010-C TNNI3-mCherry/TNNI1-EGFP dual reporter cl. 74)
BIONi010-C-24
(BIONi010-C Dox a-syn)
BIONi010-C-43
(BIONi010-C + aSNCA-wt AAVS1)
BIONi010-C-44
(BIONi010-C + aSNCA-A53T AAVS1)
BIONi010-C-64
(BIONi010-C-T2A-Nanoluciferase reporter cl. 29)
BIONi010-C-49
(BIONi010-C + synapsin-m2rtTA + SNCA-wt)
BIONi010-C-50
(BIONi010-C + synapsin-m2rtTA + SNCA-A53T)
BIONi010-C-56
(BIONi010-C-A713T-C25)
BIONi010-C-57
(BIONi010-C-A713T-C42)
BIONi010-C-58
(BIONi010-C-A713T-C1)
BIONi010-C-54
(BIONi010-C with an APOE 4/4 genotype (with two functional alleles in contrast to BIONi010-C-4))
BIONi010-C-59
(BIONi010-C-A713T-C33)
BIONi010-C-60
(BIONi010-C-R589C-C7)
BIONi010-C-61
(BIONi010-C-R589C-C16)
BIONi010-C-62
(BIONi010-C-R589C-C5)
BIONi010-C-63
(BIONi010-C-R589C-C9)
BIONi010-C-48
(BIONi010-C hMDR1)
BIONi010-C-45
(BIONi010-C iCRE AAVS1 GBA1 LoxP EX5-6)
BIONi010-C-41
(BIONi010-C + iNGN2 Two-plasmid system/CRISPR-2)
BIONi010-C-65
(BiONI010-C-O16)
BIONi010-C-66
(BIONi010-C-N7)
BIONi010-C-42
(BIONi010-C + iCRE AAVS1)
BIONi010-A
(K1P53)
BIONi010-B
(K2P53, BIONi010-B)
Last update 6th March 2024
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Bioneer (BION)
Contact:
EBiSC
Owner Bioneer (BION)
Distributors
Derivation country Denmark

External Databases

BioSamples SAMEA8093245
Cellosaurus CVCL_C9MC
Wikidata Q123030803

General Information

* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
Subclone of

Donor Information

General Donor Information

Sex male
Ethnicity Black or African-American

Phenotype and Disease related information (Donor)

Diseases No disease was diagnosed.

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

Donor Relations

Other cell lines of this donor

External Databases (Donor)

BioSamples SAMEA3105780

Ethics

Also have a look at the ethics information for the parental line BIONi010-C .
Is there an MTA available for the cell line? No
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?
Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? No

hIPSC Derivation

General

The source cell information can be found in the parental cell line BIONi010-C.
Passage number reprogrammed 36

Reprogramming method

Vector type Non-integrating
Vector Episomal
Is reprogramming vector detectable?
No
Methods used
PCR

Vector free reprogramming

Other

Derived under xeno-free conditions
Unknown
Derived under GMP?
Unknown
Available as clinical grade?
Unknown

Culture Conditions

Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
O2 Concentration 5 %
CO2 Concentration 5 %
Medium mTeSR™ 1
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
No

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
SSEA-1
No
SSEA-4
Yes
TRA 1-60
Yes
POU5F1 (OCT-4)
Yes
Morphology pictures
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro directed differentiation
Marker Expressed
CXCR4
Yes
Gata6
Yes
SOX17
Yes
Mesoderm
Ont Id: UBERON_0000926
In vitro directed differentiation
Marker Expressed
BRACHYURY
Yes
VIM
Yes
MIXL1
Yes
Ectoderm
Ont Id: UBERON_0000924
In vitro directed differentiation
Marker Expressed
HES5
Yes
PAX6
Yes
NEUROD1
Yes

Microbiology / Virus Screening

HIV 1 Negative
HIV 2 Negative
Hepatitis B Negative
Hepatitis C Negative

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46,XY
Passage number: 27

Other Genotyping (Cell Line)

Is there genome-wide genotyping or functional data available?
Yes
SNP typing array
No larger chromosomal aberrations observed

Genetic Modification

Genetic modifications not related to a disease
Isogenic modification
Homozygous
APOE2/2
Mutated